Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Final Thoughts From ASH 2019 in CLL

December 24th 2019

Novel Combinations in Development for CLL

December 24th 2019

PI3K Inhibitors in R/R CLL

December 24th 2019

BTK Inhibitors in R/R CLL

December 24th 2019

Venetoclax in R/R CLL

December 24th 2019

Progression on Frontline Ibrutinib in CLL

December 24th 2019

Resistance Mechanisms Associated With BTK Inhibitors

December 24th 2019

Ibrutinib + Venetoclax for Frontline CLL

December 24th 2019

MRD Testing for CLL

December 24th 2019

Obinutuzumab + Venetoclax for Frontline CLL

December 24th 2019

Comparison of BTK Inhibitors for CLL

December 24th 2019

Toxicities With BTK Inhibitors for CLL

December 24th 2019

Frontline Antibodies With BTK Inhibitors for CLL

December 24th 2019

Up-front Ibrutinib Versus FCR for Patients With CLL

December 24th 2019

Risk Assessment in Newly Diagnosed CLL

December 24th 2019

Dr. Fakhri on Ibrutinib-Containing Regimens in CLL

December 21st 2019

Bita Fakhri, MD, MPH, discusses the trials that led to ibrutinib-containing regimens becoming the standard of care for chronic lymphocytic leukemia over traditional chemotherapy options.

Dr. Davids on Cost Effectiveness of Time-Limited Therapy With Venetoclax/Obinutuzumab in CLL

December 20th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).

Dr. Mato on the CLL14 Trial Results in CLL

December 19th 2019

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Building on BTK Inhibition in CLL

December 18th 2019

Anthony R. Mato, MD, MSCE, discusses recent treatment advances that have been made in the frontline and relapsed/refractory settings of chronic lymphocytic leukemia.

Sharman Showcases Frontline Acalabrutinib Activity in CLL

December 16th 2019

Jeff P. Sharman, MD, discusses updated data from the ELEVATE-TN trial and ongoing research that is poised to define the optimal role of acalabrutinib in chronic lymphocytic leukemia.